



Cross4Health

Awarded Projects Interview

Awarded Project	Fenomino Asthma Analyzer
Company name	GoClinic B.V.

1. What is the company's business activity?

At GoClinic, we are addressing the challenge of lacking infrastructure and interoperability (between healthcare facilities) that prevents data from being exchanged in a meaningful and effective way. In times such as these, healthcare institutions need to leverage modern AI-based prediction tools (based on previously collected health records, data analytics, and population-wide metrics for a better fast-acting informed decision making.

But these tools can only be leveraged when the data are structured in (homogenous manner) both at syntactic and semantic levels. It is not possible to perform learn patterns, predictions, anomalies of data or make recommendations when the data sources are emerging from different non-homogenous providers. Therefore, having patient-generated data collected from the horizontal level such as mobile apps, wearables, and sensors would facilitate its vertical level exchange directly with the industrial-standard syntactic and semantic formats.

We are facilitating data exchange between patients and healthcare institutions by using HL7 FHIR and industry-standard terminologies (i.e. Snomed, Loinc, etc). This assures that the patient-generated data is easily (comprehended) ingested by hospital data repositories and analytics.

2. What is the Fenomino Asthma Analyzer project?

Innovative concept solution focusing on Asthma patients, combining personalized patient breath analysis with outdoor air condition for a smart patient treatment and adaptive conditioning with environment surrounding.

With Fenomino you can relate your asthma with your personalized exhaled breath, current weather data - pollen data, air pollution and dust. For this purpose we are developing a breath tester, analysing the degree of inflammation in the respiratory system of asthma patients¹. Combined with weather data, long-term monitoring can help indicate allergenic conditions and early intervention can be realized, which also will help in tailoring the treatment and can be used as predictors to treatment response.

3. How did the idea come about?

Over the last weeks the concept and participating members have matured. The product concept was adopted to solve a tangible healthcare problem by focussing on asthma patients. Furthermore, with our new strategic partner innoViva GmbH we added team with combined 15+ years in air quality analysis for healthcare purposes.

4. Who are the core partners of the project?

GoClinic B.V. (ICT health) (founded in 2016, Nijmegen, Netherlands). The team conducted several thousand hours of research and IT development in hospital-patient relationships and hospital's ICT problems in Germany, Netherlands, Austria and Finland.

Poligy GmbH (energy) (founded in 2018) is revolutionizing the renewable energy market by using a newly developed material the "Bipolymer" by Martin Huber. The company was founded in October 2018 in Düsseldorf, Germany.

innoVIVA GmbH (medical device) (founded in 2018) is a spin-off company of the university clinic, of the Heinrich-Heine-University Düsseldorf. Its core business is the development and sales of breath tests in the medtech and healthcare market.

5. How did this collaboration between the partners arise?

Between GoClinic B.V. and poligy GmbH due to the C4H hackathon in Bochum 2019. Then the founder of poligy, Martin Huber, attracted innoVIVA GmbH to this project. As both companies had previously been exhibiting together at innovative startup events.

6. How did you hear about the Cross4Health project?

The challenge concept was developed at the Cross4Health Hackathon in Bochum, where Martin Huber (Poligy GmbH) and Artur Steffen (GoClinic B.V.) won the 3rd prize with their concept Airalyzer.

We decided to continue this project in a more professional way, by applying to the Cross4Health program.

7. What is the current status of the project?

The partners have created a MVP prototype. Ready to be tested with patients. Due to the Corona pandemic, physical patient testing got much more complicated, especially as there is just one prototype, that cannot be sent via mail to potential testers.

8. What are the next steps?

To all parties of our C4H consortium the impact of the Corona pandemic is strongly noticeable. The prototype has to be tested with patients within a study. Once it is finalized, the Fenomino Asthma Analyzer can be promoted for financial support for introducing to the market.

9. How Cross4health can support the development of your project?

Providing access to media, press, investor and funding network.

10. Would you recommend Cross4Health to other companies?

Yes, definitely. It is a great chance to explore opportunities that can help one's business from the other spheres. Hence, the selection process of such opportunities needs to be very careful due to keeping the focus on own company and product development.